|Application ||WB, E|
|Other Names||CG10523-PB; isoform B; Cg10523-pc; isoform c; PARKIN; park; parkin;|
|Target/Specificity||This Drosophila Parkin antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 82-111 amino acids from the N-terminal region of human Drosophila Parkin.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||Drosophila Parkin Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Functions within a multiprotein E3 ubiquitin ligase complex, catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins.|
Provided below are standard protocols that you may find useful for product applications.
Parkin is thought to play a role in the ubiquitin/proteasome pathway for protein degradation. The amino terminus bears sequence homology to ubiquitin while functionally it acts as a RING-type ubiquitin protein ligase (E3) that coordinates the transfer of ubiquitin to substrate proteins, thus targeting them for degradation by the proteasome. Mutations in the human version of the protein are known to cause autosomal recessive juvenile parkinsonism.
Zhong,L. et al. J. Biol. Chem. 280 (10), 9425-9430 (2005)
Pesah,Y. et al. Development 131 (9), 2183-2194 (2004)
Haywood,A.F. et al. BMC Neurosci 5, 14 (2004)
Finney,N. et al. J. Biol. Chem. 278 (18), 16054-16058 (2003)
Yang,Y. et al. Neuron 37 (6), 911-924 (2003)